Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Q2 2024 Earnings Conference Call July 23, 2024 8:30 AM ET

Company Participants

Rachel Frank – Head of Investor Relations
Sanj K. Patel – Chief Executive Officer
Ross Moat – Chief Commercial Officer
Mark Ragosa – Chief Financial Officer
John Paolini – Chief Medical Officer

Conference Call Participants

Anupam Rama – JPMorgan
Eva Fortea-Verdejo – Wells Fargo
Liisa Bayko – Evercore ISI

Operator

Good day and thank you for standing by. Welcome to Kiniksa Pharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time all participants are in listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded.

I will now hand the conference over to your speaker for today, Rachel Frank, Head of Investor Relations. Please go ahead.

Rachel Frank

Thank you, operator. Good morning everyone and thank you for joining Kiniksa call to discuss our second quarter 2024 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Next, Ross Moat, our Chief Commercial Officer, will provide an update on the ARCALYST commercial execution. From there, Mark Ragosa, our Chief Financial Officer, will review our second quarter 2024 financial results. And finally, Sanj will return for closing remarks and to kick off the Q&A session, for which Eben Tessari, our Chief Operating Officer; and John Paolini, our Chief Medical Officer, will also be on the line.

Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption Risk Factors contained in our SEC filings. These statements speak only as of the date of this presentation and we undertake no obligation to update such statements, except as required by law.

With that, I will turn it over to Sanj.

Sanj K. Patel

Thanks, Rachel, and hello to everyone listening in. In this second quarter of the year, we've continued to execute and make significant progress across our portfolio. We've driven strong commercial performance and advanced our clinical stage asset abiprubart into a Phase 2b study in Sjögren's Disease. The full clinical development plan for this program is fully funded within our current operating plan. We've also maintained a strong financial position, and we expect to be cash flow positive on an annual basis. All of this positions us for continued success in the second half of the year and beyond.